Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Sherman Clinical Research

Neither a doctor nor a teaching hospital

Research payments

$1,402,715

259 payments

Through program year 2025, Sherman Clinical Research is reported as receiving $1,402,715 in research payments, across 259 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $215,074 28
2024 Research $219,193 27
2023 Research $206,508 30
2022 Research $203,965 53
2021 Research $181,121 47
2020 Research $233,851 43
2019 Research $143,003 31

Breakdown

Who paid Research payments · program years 2019–2025
  1. Genentech, Inc. $426,261 68 payments
  2. Sanofi US Services Inc. $304,664 68 payments
  3. Mylan Specialty L.P. $155,782 22 payments
  4. Cipla USA Inc. $106,969 22 payments
  5. GlaxoSmithKline, LLC. $96,475 27 payments
  6. Teva Pharmaceuticals USA, Inc. $88,271 27 payments
  7. Amgen Inc. $64,340 1 payment
  8. Paratek Pharmaceuticals, Inc. $58,826 6 payments
  9. Novartis Pharmaceuticals Corporation $44,111 4 payments
  10. Hoffmann-La Roche Limited $32,534 10 payments
Studies the money was for Research payments · program years 2019–2025
  1. PH Iib of Astegolimab in COPD $244,814 52 payments
  2. Ph III OLE of Astegolimab in COPD $213,981 26 payments
  3. A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation $160,447 35 payments
  4. Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) $137,718 32 payments
  5. A Phase 4, Randomized, Double-Blind, Double-Dummy, Parallel Group Study Comparing Improvements in Lung Function in Adults With Severe to Very Severe Chronic Obstructive Pulmonary Disease and Suboptimal Inspiratory Flow Rate Following Once-Daily Treatment Over 12 Weeks With Either Revefenacin Inhalation Solution Delivered via Standard Jet Nebulizer or Tiotropium Delivered via a Dry Powder Inhaler (Spiriva HandiHaler) $88,664 11 payments
  6. A Randomized, Blinded, Parallel Group, Placebo-Controlled, Multiple Dose, Multicenter Study to Compare the Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 mcg, to Flovent HFA 110 mcg, in Adult Subjects With Asthma $88,271 27 payments
  7. U-Fs-Mu-As3120 $81,869 19 payments
  8. A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Maridebart Cafraglutide on Mortality and Morbidity in Participants Living With Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity (MARITIME-HF) $64,340 1 payment
  9. A Phase 1 Multi-Center Study to Measure the Pharmacokinetics of Oral Omadacycline in Adult Subjects With Community-Acquired Bacterial Pneumonia (CABP) $58,826 6 payments
  10. A Randomized, Adaptive, Double-Blind, Placebo-Controlled, Parallel-Arm $49,600 10 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record